MDx Sales Drive 42 Percent Increase in Q3 Revenues for Myriad Genetics

Myriad's revenues grew 42 percent, but investors sent the firm's shares down in early Tuesday trade as investors looked for greater molecular diagnostics growth.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories